Targeted Therapies and Your Lung Cancer
Researchers are learning more about what makes lung cancer cells form, grow, and spread. Every cell in the body has the same library of genes that acts as the blueprint for everything else that makes up a cell and makes it work. In cancer cells, damage to these genes (mutations) is responsible for the cells becoming cancerous. Some of these mutations create proteins in cells that act like a stuck gas pedal in your car to make it drive out of control. These mutant proteins in cancer cells are good “targets” for new drugs. These drugs are known as TARGETED THERAPIES. Targeted therapies work by blocking these mutant proteins, which prevents them from growing and spreading, while not harming normal cells. Tarceva® (Erlotinib), Gilogrif® (Afatanib), Xalkori® (Crizotinib) and Zykadia® (Ceritinib) are examples of FDA-approved drugs that target the mutated proteins, some of which are referred to as “receptors” that are driving the cancer cells out of control.
Targeted Therapies – Questions with Answers by Our Experts
LCFA has prepared a brochure (updated December, 2014) with all of the information contained in this area of our website. We are happy to share this valuable information with you:
Targeted Therapies Brochure (in .pdf format to print yourself and take to your physician)
Or – please email us at CIker@LCFAmerica.org with your request and we’ll mail the brochure to the address you specify.
The information contained in this section of the LCFA website is meant for informational purposes only. It does not replace the advice of a licensed healthcare provider. It is recommended that you consult with a licensed healthcare provider about your diagnosis, treatment and general care.